Catalyst Pharmaceuticals (CPRX) EPS (Basic) (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of EPS (Basic) data on file, last reported at $0.52 in Q1 2026.

• Quarterly EPS (Basic) rose 11.61% year-over-year to $0.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.89 (up 16.29% YoY) and the FY2025 annual result came in at $1.83, up 32.38% from the prior year.
• EPS (Basic) improved to $0.52 in Q1 2026, from $0.51 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.52 in Q1 2026 to a low of -$0.29 in Q3 2023.
• A 5-year average of $0.3 and a median of $0.35 in 2024 frame the typical range for EPS (Basic).
• Annual changes were most pronounced in 2023 — EPS (Basic) slumped 231.11% — and 2024, when it soared 227.82%.
• Tracing CPRX's EPS (Basic) over 5 years: stood at $0.25 in 2022, then tumbled by 34.93% to $0.16 in 2023, then surged by 194.53% to $0.47 in 2024, then advanced by 7.97% to $0.51 in 2025, then grew by 2.25% to $0.52 in 2026.
• The last three EPS (Basic) figures came in at $0.52 (Q1 2026), $0.51 (Q4 2025), and $0.43 (Q3 2025), per Business Quant data.